235 related articles for article (PubMed ID: 33374919)
21. Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
Peterková L; Kmoníčková E; Ruml T; Rimpelová S
J Med Chem; 2020 Mar; 63(5):1937-1963. PubMed ID: 32030976
[TBL] [Abstract][Full Text] [Related]
22. The unfolded protein response as a target for anticancer therapeutics.
Wang M; Law ME; Castellano RK; Law BK
Crit Rev Oncol Hematol; 2018 Jul; 127():66-79. PubMed ID: 29891114
[TBL] [Abstract][Full Text] [Related]
23. Inhibitor of sarco-endoplasmic reticulum Ca2+-ATPase thapsigargin stimulates production of nitric oxide and secretion of interferon-gamma.
Kmonícková E; Melkusová P; Harmatha J; Vokác K; Farghali H; Zídek Z
Eur J Pharmacol; 2008 Jun; 588(1):85-92. PubMed ID: 18457829
[TBL] [Abstract][Full Text] [Related]
24. A diversity of SERCA Ca2+ pump inhibitors.
Michelangeli F; East JM
Biochem Soc Trans; 2011 Jun; 39(3):789-97. PubMed ID: 21599650
[TBL] [Abstract][Full Text] [Related]
25. Exposure to tributyltin induces endoplasmic reticulum stress and the unfolded protein response in zebrafish.
Komoike Y; Matsuoka M
Aquat Toxicol; 2013 Oct; 142-143():221-9. PubMed ID: 24055755
[TBL] [Abstract][Full Text] [Related]
26. Rh(I)-Catalyzed Allenic Pauson-Khand Reaction to Access the Thapsigargin Core: Influence of Furan and Allenyl Chloroacetate Groups on Enantioselectivity.
Deihl ED; Jesikiewicz LT; Newman LJ; Liu P; Brummond KM
Org Lett; 2022 Feb; 24(4):995-999. PubMed ID: 35081313
[TBL] [Abstract][Full Text] [Related]
27. Derivatives of thapsigargin as probes of its binding site on endoplasmic reticulum Ca2+ ATPase. Stereoselectivity and important functional groups.
Christensen SB; Andersen A; Poulsen JC; Treiman M
FEBS Lett; 1993 Dec; 335(3):345-8. PubMed ID: 8262181
[TBL] [Abstract][Full Text] [Related]
28. Total synthesis of two novel subpicomolar sarco/endoplasmatic reticulum Ca2+-ATPase inhibitors designed by an analysis of the binding site of thapsigargin.
Søhoel H; Liljefors T; Ley SV; Oliver SF; Antonello A; Smith MD; Olsen CE; Isaacs JT; Christensen SB
J Med Chem; 2005 Nov; 48(22):7005-11. PubMed ID: 16250659
[TBL] [Abstract][Full Text] [Related]
29. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
Denmeade SR; Isaacs JT
Cancer Biol Ther; 2005 Jan; 4(1):14-22. PubMed ID: 15662118
[TBL] [Abstract][Full Text] [Related]
30. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps.
Lytton J; Westlin M; Hanley MR
J Biol Chem; 1991 Sep; 266(26):17067-71. PubMed ID: 1832668
[TBL] [Abstract][Full Text] [Related]
31. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase.
Thastrup O; Cullen PJ; Drøbak BK; Hanley MR; Dawson AP
Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2466-70. PubMed ID: 2138778
[TBL] [Abstract][Full Text] [Related]
32. Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.
Zimmermann T; Christensen SB; Franzyk H
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914143
[TBL] [Abstract][Full Text] [Related]
33. Targeting the unfolded protein response in cancer.
Ojha R; Amaravadi RK
Pharmacol Res; 2017 Jun; 120():258-266. PubMed ID: 28396092
[TBL] [Abstract][Full Text] [Related]
34. The Ca2+ pump inhibitor, thapsigargin, inhibits root gravitropism in Arabidopsis thaliana.
Urbina DC; Silva H; Meisel LA
Biol Res; 2006; 39(2):289-96. PubMed ID: 16874404
[TBL] [Abstract][Full Text] [Related]
35. Toward the synthesis of thapsigargin: enantioselective synthesis of 7,11-dihydroxyguaianolides.
Manzano FL; Guerra FM; Moreno-Dorado FJ; Jorge ZD; Massanet GM
Org Lett; 2006 Jun; 8(13):2879-82. PubMed ID: 16774280
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium.
Dubois C; Vanden Abeele F; Sehgal P; Olesen C; Junker S; Christensen SB; Prevarskaya N; Møller JV
FEBS J; 2013 Nov; 280(21):5430-40. PubMed ID: 23927406
[TBL] [Abstract][Full Text] [Related]
37. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
38. Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin.
Andrews SP; Tait MM; Ball M; Ley SV
Org Biomol Chem; 2007 May; 5(9):1427-36. PubMed ID: 17464412
[TBL] [Abstract][Full Text] [Related]
39. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a.
Younce CW; Burmeister MA; Ayala JE
Am J Physiol Cell Physiol; 2013 Mar; 304(6):C508-18. PubMed ID: 23302777
[TBL] [Abstract][Full Text] [Related]
40. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.
Furuya Y; Lundmo P; Short AD; Gill DL; Isaacs JT
Cancer Res; 1994 Dec; 54(23):6167-75. PubMed ID: 7954463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
